View Future GrowthODI Pharma 과거 순이익 실적과거 기준 점검 0/6ODI Pharma은 연평균 10%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 8.8%의 비율로 증가했습니다. 매출은 연평균 64.5%의 비율로 증가했습니다.핵심 정보9.98%순이익 성장률12.54%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률64.52%자기자본이익률-37.46%순이익률-3.62%다음 순이익 업데이트28 May 2026최근 과거 실적 업데이트공시 • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026공시 • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025공시 • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025공시 • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.공시 • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024모든 업데이트 보기Recent updatesBoard Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. CEO & Director Jan-Mark Edewaard was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026공시 • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025공시 • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025공시 • Dec 30ODI Pharma AB (publ) Appoints Jan-Mark Edewaard as Board MemberODI Pharma AB (publ) announced that at the AGM held on December 30, 2024, approved the appointment of Jan-Mark Edewaard as board member.공시 • Dec 12ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million.ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million. Security Name: Shares Security Type: Common Stock Securities Offered: 695,034 Price\Range: SEK 3.22 Transaction Features: Rights Offering공시 • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.공시 • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024Reported Earnings • Jun 04Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.085 (up from kr0.062 loss in 3Q 2023). Revenue: kr13.9m (up kr13.9m from 3Q 2023). Net income: kr1.30m (up kr2.24m from 3Q 2023). Profit margin: 9.3% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.공시 • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.공시 • May 01ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024ODI Pharma AB (publ) announced that they will report Q3, 2024 results on May 30, 2024Reported Earnings • Feb 25Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.062 (up from kr0.11 loss in 2Q 2023). Revenue: kr2.95m (up kr2.88m from 2Q 2023). Net income: kr946.5k (up kr2.68m from 2Q 2023). Profit margin: 32% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.공시 • Jan 24ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024ODI Pharma AB (publ) announced that they will report Q2, 2024 results on Feb 22, 2024Reported Earnings • Nov 26First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023)First quarter 2024 results: kr0.095 loss per share (improved from kr0.10 loss in 1Q 2023). Revenue: kr534.3k (up kr506.3k from 1Q 2023). Net loss: kr1.44m (loss narrowed 10.0% from 1Q 2023).공시 • Nov 24ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Nov 24, 2023공시 • Nov 14ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023, at 10:30 Central European Standard Time. Location: In the office of the company at Östermalmstorg 1, 114 42 Stockholm Stockholm Sweden Agenda: To consider the presentation of the annual report and auditor's report; to consider the adoption of the income statement and the balance sheet; to consider allocation of the company's result according to the adopted balance sheet; to consider discharge from liability for board members and the managing director; to consider determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors; to consider the election of the Board of Directors and accounting firm or auditors; and to consider other matters.공시 • Oct 25ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023ODI Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 23, 2023Reported Earnings • Aug 27Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022)Full year 2023 results: kr0.41 loss per share (improved from kr0.48 loss in FY 2022). Net loss: kr6.16m (loss narrowed 15% from FY 2022).공시 • Jul 26ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Aug 24, 2023공시 • Jan 25+ 1 more updateODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish MarketODI Pharma AB announces that the Company has received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)in Polandfor its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market. The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on the Polish medical market. The Company will now proceed with the necessary steps to bring the products to the Polish market as soon as possible, through its subsidiary ODI Pharma Polska Sp. z o.o.공시 • Nov 17ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.매출 및 비용 세부 내역ODI Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:6OD 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Dec 2520-16030 Sep 259-56030 Jun 253-66031 Mar 2510-65031 Dec 2422-47030 Sep 2422-17030 Jun 2422-17031 Mar 2415-28031 Dec 231-46030 Sep 231-76030 Jun 230-76031 Mar 230-76031 Dec 220-88030 Sep 220-87030 Jun 220-77031 Mar 221-77031 Dec 210-54030 Sep 210-44030 Jun 210-44031 Mar 210-37031 Dec 200-57030 Sep 200-66030 Jun 200-55031 Mar 200-53031 Dec 190-31030 Sep 190-320양질의 수익: 6OD 은(는) 현재 수익성이 없습니다.이익 마진 증가: 6OD는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 6OD는 수익성이 없지만 지난 5년 동안 연평균 10%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 6OD의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 6OD은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(16.1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 6OD는 현재 수익성이 없으므로 자본 수익률이 음수(-37.46%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 14:54종가2026/05/26 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ODI Pharma AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025
공시 • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025
공시 • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024
Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
공시 • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. CEO & Director Jan-Mark Edewaard was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025
공시 • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025
공시 • Dec 30ODI Pharma AB (publ) Appoints Jan-Mark Edewaard as Board MemberODI Pharma AB (publ) announced that at the AGM held on December 30, 2024, approved the appointment of Jan-Mark Edewaard as board member.
공시 • Dec 12ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million.ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million. Security Name: Shares Security Type: Common Stock Securities Offered: 695,034 Price\Range: SEK 3.22 Transaction Features: Rights Offering
공시 • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024
Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
공시 • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024
Reported Earnings • Jun 04Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.085 (up from kr0.062 loss in 3Q 2023). Revenue: kr13.9m (up kr13.9m from 3Q 2023). Net income: kr1.30m (up kr2.24m from 3Q 2023). Profit margin: 9.3% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
공시 • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.
공시 • May 01ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024ODI Pharma AB (publ) announced that they will report Q3, 2024 results on May 30, 2024
Reported Earnings • Feb 25Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.062 (up from kr0.11 loss in 2Q 2023). Revenue: kr2.95m (up kr2.88m from 2Q 2023). Net income: kr946.5k (up kr2.68m from 2Q 2023). Profit margin: 32% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
공시 • Jan 24ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024ODI Pharma AB (publ) announced that they will report Q2, 2024 results on Feb 22, 2024
Reported Earnings • Nov 26First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023)First quarter 2024 results: kr0.095 loss per share (improved from kr0.10 loss in 1Q 2023). Revenue: kr534.3k (up kr506.3k from 1Q 2023). Net loss: kr1.44m (loss narrowed 10.0% from 1Q 2023).
공시 • Nov 24ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Nov 24, 2023
공시 • Nov 14ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023, at 10:30 Central European Standard Time. Location: In the office of the company at Östermalmstorg 1, 114 42 Stockholm Stockholm Sweden Agenda: To consider the presentation of the annual report and auditor's report; to consider the adoption of the income statement and the balance sheet; to consider allocation of the company's result according to the adopted balance sheet; to consider discharge from liability for board members and the managing director; to consider determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors; to consider the election of the Board of Directors and accounting firm or auditors; and to consider other matters.
공시 • Oct 25ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023ODI Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 23, 2023
Reported Earnings • Aug 27Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022)Full year 2023 results: kr0.41 loss per share (improved from kr0.48 loss in FY 2022). Net loss: kr6.16m (loss narrowed 15% from FY 2022).
공시 • Jul 26ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Aug 24, 2023
공시 • Jan 25+ 1 more updateODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish MarketODI Pharma AB announces that the Company has received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)in Polandfor its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market. The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on the Polish medical market. The Company will now proceed with the necessary steps to bring the products to the Polish market as soon as possible, through its subsidiary ODI Pharma Polska Sp. z o.o.
공시 • Nov 17ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.